Paul Choi
Stock Analyst at Goldman Sachs
(3.84)
# 679
Out of 4,996 analysts
109
Total ratings
52.86%
Success rate
9.92%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $16.05 | +24.61% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $39.04 | +20.39% | 1 | Sep 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $16.00 | -25.00% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $18.34 | -83.64% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $2.70 | +196.30% | 6 | May 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $11.78 | -57.56% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $8.27 | -3.26% | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $37.98 | +36.91% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $5.49 | +282.51% | 8 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $9.65 | +24.35% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.65 | +13.21% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $10 | $9.78 | +2.25% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $191.99 | +17.19% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $50.61 | +182.55% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $58.99 | -28.80% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $50.40 | +19.05% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $15.64 | +21.48% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $36.49 | -12.30% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $50.05 | -0.10% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.86 | +290.95% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $12.31 | +306.17% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.48 | +1,589.19% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $15.00 | +1,033.33% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $4.84 | +65.29% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $142.00 | -4.93% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $58.50 | +412.82% | 2 | Mar 30, 2020 |
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $16.05
Upside: +24.61%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $39.04
Upside: +20.39%
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $16.00
Upside: -25.00%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $18.34
Upside: -83.64%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.70
Upside: +196.30%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $11.78
Upside: -57.56%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $8.27
Upside: -3.26%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $37.98
Upside: +36.91%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $5.49
Upside: +282.51%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $9.65
Upside: +24.35%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $2.65
Upside: +13.21%
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $9.78
Upside: +2.25%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $191.99
Upside: +17.19%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $50.61
Upside: +182.55%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $58.99
Upside: -28.80%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $50.40
Upside: +19.05%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $15.64
Upside: +21.48%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $36.49
Upside: -12.30%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $50.05
Upside: -0.10%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.86
Upside: +290.95%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $12.31
Upside: +306.17%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.48
Upside: +1,589.19%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $15.00
Upside: +1,033.33%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $4.84
Upside: +65.29%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $142.00
Upside: -4.93%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $58.50
Upside: +412.82%